Screening for Type 2 Diabetes Mellitus: A Systematic Review for the U.S. Preventive Services Task Force
The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Screening for type 2 diabetes mellitus could lead to earlier identification and treatment of asymptomatic diabetes, impaired fasting glucose (IFG), or impaired glucose tolerance (IGT), potentially resulting in improved outcomes. PURPOSE: To update the 2008 U.S. Preventive Services Task Force review on diabetes screening in adults. DATA SOURCES: Cochrane databases and MEDLINE (2007 through October 2014) and relevant studies from previous Task Force reviews. STUDY SELECTION: Randomized, controlled trials; controlled, observational studies; and systematic reviews. DATA EXTRACTION: Data were abstracted by 1 investigator and checked by a second; 2 investigators independently assessed study quality. DATA SYNTHESIS: In 2 trials, screening for diabetes was associated with no 10-year mortality benefit versus no screening (hazard ratio, 1.06 [95% CI, 0.90 to 1.25]). Sixteen trials consistently found that treatment of IFG or IGT was associated with delayed progression to diabetes. Most trials of treatment of IFG or IGT found no effects on all-cause or cardiovascular mortality, although lifestyle modification was associated with decreased risk for both outcomes after 23 years in 1 trial. For screen-detected diabetes, 1 trial found no effect of an intensive multifactorial intervention on risk for all-cause or cardiovascular mortality versus standard control. In diabetes that was not specifically screen-detected, 9 systematic reviews found that intensive glucose control did not reduce risk for all-cause or cardiovascular mortality and results for intensive blood pressure control were inconsistent. LIMITATION: The review was restricted to English-language articles, and few studies were conducted in screen-detected populations. CONCLUSION: Screening for diabetes did not improve mortality rates after 10 years of follow-up. More evidence is needed to determine the effectiveness of treatments for screen-detected diabetes. Treatment of IFG or IGT was associated with delayed progression to diabetes. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
1 retracted
Hemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T. P., & Wetterslev, J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub3 · Cited by 203
RetractedMeasuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“Statistical heterogeneity was assessed using the I(2) statistic (26).”
MethodReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 5×
“Chiasson et al, 2002 (51)* Knowler et al, 2002 (7)* Gernstein et al, 2006 (52)* Holman et al, 2010 (28) Ramachandran et al, 2009 (48) M-H overall (I2 = 0.0”
BackgroundInfluentialDiagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“…incidence of progression to DM. Knowler et al, 2002 (7)* Katula et al, 2013 (88) Kosaka et al, 2005 (8)* Li et al, 2014 (38) Lindahl et al, 2009 (87) Penn et al, 2009 (84) Ramachandran et al, 2006 (10)* Saito et al, 2011 (40) Sakane et al, 2011 (86) Tuomilehto et al, 2001 (9)* D+L overall (I2 = 77”
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Research works printed but not linked: 4
- Centers for Disease Control and Prevention (CDC), 2012, MMWR Morb Mortal Wkly Rep, 61, 918
- American Diabetes Association, 2015, Diabetes Care, 38, S1
- Van den Donk M, 2013, Diabetologia
- Wu H, 2010, Chin Med J (Engl), 123, 2908
Cited by
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Diabetes Care · doi:10.2337/dci23-0036 · Cited by 351
Manne-Goehler, J., Geldsetzer, P., Agoudavi, K., Andall-Brereton, G., Aryal, K. K., Bicaba, B. W., Bovet, P., Brian, G., Dorobantu, M., Gathecha, G., et al. (2019) · PLOS Medicine · doi:10.1371/journal.pmed.1002751 · Cited by 324
Siu, A. L., & on behalf of the U.S. Preventive Services Task Force* (2015) · Annals of Internal Medicine · doi:10.7326/m15-2345 · Cited by 319
Hemmingsen, B., Gimenez-Perez, G., Mauricio, D., Roqué i Figuls, M., Metzendorf, M.-I., & Richter, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003054.pub4 · Cited by 316
General health checks in adults for reducing morbidity and mortality from disease
Krogsbøll, L. T., Jørgensen, K. J., & Gøtzsche, P. C. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009009.pub3 · Cited by 202
Metadata
- Authors
- Selph, S., Dana, T., Blazina, I., Bougatsos, C., Patel, H., & Chou, R.
- Affiliations
- Oregon Health & Science University (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2015-06-02
- Volume
- 162
- Issue
- 11
- Pages
- 765-776
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2086557545
- Semantic Scholar
- 71271d7cc0522ec02fb4af61d3f48ff903988f34
- Cited by
- 134
- References
- 89
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 8 · 2023: 13 · 2022: 7 · 2021: 12 · 2020: 24 · 2019: 3 · 2018: 19 · 2017: 12 · 2016: 23 · 2015: 8
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (HHSA 290-2007-10057-I)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, diabetes screening, impaired fasting glucose, impaired glucose tolerance, screen-detected diabetes, progression to diabetes, lifestyle modification, tight glycemic control, intensive blood pressure control, cardiovascular mortality, all-cause mortality, USPSTF recommendations
- MeSH terms
- Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Fasting, Humans, Life Style, Mass Screening, United States, Glucose Intolerance, Disease Progression, Risk Assessment, Early Diagnosis, Asymptomatic Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Screening for Type 2 Diabetes Mellitus: A Systematic Review for the U.S. Preventive Services Task Force. https://app.cochat.ai/papers/10.7326/m14-2221
- The paper
- Selph, S., Dana, T., Blazina, I., Bougatsos, C., Patel, H., & Chou, R. (2015). Screening for Type 2 Diabetes Mellitus: A Systematic Review for the U.S. Preventive Services Task Force. Annals of Internal Medicine. https://doi.org/10.7326/m14-2221
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.